Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R S Benjamin

Showing results (131-140 of 258) with videos related to

Pageof 26
Sort By:
Cancer Treatment Reports|March 1, 1981
Phase II evaluation of AMSA in adult sarcomasB S Yap, C Plager, R S Benjamin, et al.
Drug Metabolism Reviews|January 1, 1978
Metabolism and disposition of Baker's antifolate (NSC-139105), ftorafur (NSC-148958), and dichloroallyl lawsone (NSC-126771) in manT L Loo, R S Benjamin, K Lu, et al.
Pediatric Radiology|January 1, 1982
Intraarterial management of giant-cell tumors of the spine in childrenF Eftekhari, S Wallace, V P Chuang, et al.
Cancer Treatment Reports|December 1, 1982
Doxorubicin-DNA complex: a phase I clinical trialS W Hall, R S Benjamin, M A Burgess, et al.
Cancer|June 15, 1981
A phase II evaluation of methyl CCNU and actinomycin D in the treatment of advanced sarcomas in adultsB S Yap, R S Benjamin, M A Burgess, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependenceS R Patel, S Vadhan-Raj, N Papadopolous, et al.
Cancer|September 15, 1985
Doxorubicin-induced congestive heart failure in adultsM M Haq, S S Legha, J Choksi, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Phase I clinical trial and pharmacokinetic evaluation of 4'-0-tetrahydropyranyladriamycin (THP-adriamycin)M N Raber, R A Newman, K Lu, et al.
Neurosurgery|May 12, 2000
Pituitary carcinoma containing gonadotropins: treatment by radical excision and cytotoxic chemotherapy: case reportI E McCutcheon, D R Pieper, G N Fuller, et al.
Oncology Reports|April 11, 2001
Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedulesS G Berrak, M S Ewer, N Jaffe, et al.
Pageof 26

Showing results (131-140 of 258) with videos related to

Sort By:
Pageof 26
Cancer Treatment Reports|March 1, 1981
Phase II evaluation of AMSA in adult sarcomasB S Yap, C Plager, R S Benjamin, et al.
Drug Metabolism Reviews|January 1, 1978
Metabolism and disposition of Baker's antifolate (NSC-139105), ftorafur (NSC-148958), and dichloroallyl lawsone (NSC-126771) in manT L Loo, R S Benjamin, K Lu, et al.
Pediatric Radiology|January 1, 1982
Intraarterial management of giant-cell tumors of the spine in childrenF Eftekhari, S Wallace, V P Chuang, et al.
Cancer Treatment Reports|December 1, 1982
Doxorubicin-DNA complex: a phase I clinical trialS W Hall, R S Benjamin, M A Burgess, et al.
Cancer|June 15, 1981
A phase II evaluation of methyl CCNU and actinomycin D in the treatment of advanced sarcomas in adultsB S Yap, R S Benjamin, M A Burgess, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 1997
High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependenceS R Patel, S Vadhan-Raj, N Papadopolous, et al.
Cancer|September 15, 1985
Doxorubicin-induced congestive heart failure in adultsM M Haq, S S Legha, J Choksi, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1989
Phase I clinical trial and pharmacokinetic evaluation of 4'-0-tetrahydropyranyladriamycin (THP-adriamycin)M N Raber, R A Newman, K Lu, et al.
Neurosurgery|May 12, 2000
Pituitary carcinoma containing gonadotropins: treatment by radical excision and cytotoxic chemotherapy: case reportI E McCutcheon, D R Pieper, G N Fuller, et al.
Oncology Reports|April 11, 2001
Doxorubicin cardiotoxicity in children: reduced incidence of cardiac dysfunction associated with continuous-infusion schedulesS G Berrak, M S Ewer, N Jaffe, et al.
Pageof 26